326676
Adjusting for comorbidities in disease expenditure studies: An application to United States national inpatient data
We apply this framework for comorbidity adjustment to the National Inpatient Survey data in the United States for years 1996-2010. For each disease, comorbidity adjustment factors are generated separately by age and sex. Our preliminary estimates suggest that mental health problems such as unipolar depressive disorders have the greatest increase in expenditure after adjustment, whereas dementia has the greatest decrease in expenditure after comorbidity adjustment.
Our methodology takes a unified approach to comorbidity, which not only accounts for excess expenditure that needs to be distributed away from a primary diagnosis, but also the inflows of expenditures that needs to be redistributed towards each disease acting as a comorbidity for other primary diagnoses. Correcting for comorbidities provides a more accurate estimates of the expenditure incurred by specific diseases.
Learning Areas:
Biostatistics, economicsPublic health or related public policy
Social and behavioral sciences
Learning Objectives:
Describe an “encounter-based approach” for health expenditure tracking.
Explain the rationale for comorbidity adjustment and the conceptual underpinnings of this particular method.
List several diseases which increase expenditure after adjustment and some which decrease expenditure.
Keyword(s): Health Care Costs, Economic Analysis
Qualified on the content I am responsible for because: I have lead the Financial Resources of Health research team at the Institute for Health Metrics and Evaluation for two years, have worked in global health and health economics for five years, and have PhD in economics. I am co-investigator or co-principal investigator on several funded grants related to tracking resources for health.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.